FDA grants authorization for digital cognitive behavioral therapy for type 2 diabetes (Healio)

Key takeaways:

• The FDA cleared AspyreRx digital cognitive behavior therapy for adults with type 2 diabetes.
• In a randomized controlled trial, the intervention was associated with a 0.28% HbA1c reduction at 90 days.

The FDA granted marketing authorization for a digital cognitive behavioral therapy intervention for adults with type 2 diabetes, according to an industry press release.